[Molecular-targeted therapy for motor neuron disease]

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• The precise mechanisms driving motor neuron degeneration in amyotrophic lateral sclerosis (ALS) are not fully understood.
• Research has explored various therapeutic strategies, including targeting mutant superoxide dismutase 1 (SOD1) and TAR DNA-binding protein 43 (TDP-43) in ALS models.
• Spinal and bulbar muscular atrophy (SBMA) pathogenesis is linked to androgen receptor (AR) accumulation, influenced by testosterone levels.

Purpose of the Study:

• To review current understanding and therapeutic targets for ALS and SBMA.
• To highlight findings from preclinical studies using SOD1 and SBMA mouse models.
• To identify potential therapeutic interventions for motor neuron diseases.

Main Methods:

• Analysis of existing clinical trial data and preclinical studies in SOD1 and SBMA mouse models.
• Investigation of the role of mutant SOD1 expression in astrocytes and its effect on microglial activation.
• Evaluation of therapeutic agents including lithium, NADPH oxidase inhibitors, free-radical scavengers, ammonium tetrathiomolybdate, heat shock protein (HSP) inhibitors, and sodium butyrate.

Main Results:

• Diminished mutant SOD1 expression in astrocytes slowed ALS progression in mice.
• Dyslipidemia showed a potential protective effect in ALS patients.
• Androgen deprivation mitigated neurodegeneration in SBMA by inhibiting pathogenic AR nuclear accumulation.
• Selective HSP inhibition improved SBMA mouse models by enhancing proteasomal degradation of pathogenic AR.
• Sodium butyrate improved neurological function in SBMA mice, but with a narrow therapeutic dose range.

Conclusions:

• Targeting specific pathways like mutant SOD1, TDP-43, and AR signaling offers potential therapeutic avenues for ALS and SBMA.
• Preclinical findings in animal models provide valuable insights for future drug development in motor neuron diseases.
• Further research is needed to translate promising preclinical results into effective human therapies for ALS and SBMA.